CA2241845A1 - 4,5-dihydronaphth[1,2-c]isoxazoles and derivatives thereof having cns activity - Google Patents

4,5-dihydronaphth[1,2-c]isoxazoles and derivatives thereof having cns activity

Info

Publication number
CA2241845A1
CA2241845A1 CA002241845A CA2241845A CA2241845A1 CA 2241845 A1 CA2241845 A1 CA 2241845A1 CA 002241845 A CA002241845 A CA 002241845A CA 2241845 A CA2241845 A CA 2241845A CA 2241845 A1 CA2241845 A1 CA 2241845A1
Authority
CA
Canada
Prior art keywords
dihydronaphth
derivatives
isoxazoles
cns activity
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002241845A
Other languages
French (fr)
Other versions
CA2241845C (en
Inventor
Nicholas J. Hrib
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2241845A1 publication Critical patent/CA2241845A1/en
Application granted granted Critical
Publication of CA2241845C publication Critical patent/CA2241845C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

4,5-Dihydronaphth[1,2-c]isoxazole derivatives of general formula (I), where A, X and n are defined herein are disclosed. Such compounds are useful as serotonin 5-HT3 antagonists. These compounds are useful for the treatment of anxiety, psychiatric disorders, nausea, vomiting and drug dependency.
CA002241845A 1996-01-05 1996-12-12 4,5-dihydronaphth[1,2-c]isoxazoles and derivatives thereof having cns activity Expired - Fee Related CA2241845C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58331996A 1996-01-05 1996-01-05
US08/583,319 1996-01-05
PCT/US1996/019569 WO1997025317A1 (en) 1996-01-05 1996-12-12 4,5-dihydronaphth[1,2-c]isoxazoles and derivatives thereof having cns activity

Publications (2)

Publication Number Publication Date
CA2241845A1 true CA2241845A1 (en) 1997-07-17
CA2241845C CA2241845C (en) 2002-10-01

Family

ID=24332609

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002241845A Expired - Fee Related CA2241845C (en) 1996-01-05 1996-12-12 4,5-dihydronaphth[1,2-c]isoxazoles and derivatives thereof having cns activity

Country Status (14)

Country Link
EP (1) EP0874833A1 (en)
JP (1) JP3161737B2 (en)
KR (1) KR100308748B1 (en)
CN (1) CN1214046A (en)
AR (1) AR005347A1 (en)
AU (1) AU710059B2 (en)
BR (1) BR9612578A (en)
CA (1) CA2241845C (en)
HU (1) HUP9903706A3 (en)
IL (1) IL125197A0 (en)
NO (1) NO983100L (en)
NZ (1) NZ325587A (en)
WO (1) WO1997025317A1 (en)
ZA (1) ZA9725B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050131051A1 (en) * 2000-08-21 2005-06-16 Shaomeng Wang 2-3-disubstituted quinuclidiness as modulators of monoamine transporters and theraperutic and diagnostic methods based thereon
NZ536109A (en) * 2002-04-02 2006-06-30 Janssen Pharmaceutica Nv Substituted amino isoxazoline derivatives and their use as anti-depressants
TW200409777A (en) 2002-08-12 2004-06-16 Janssen Pharmaceutica Nv C-substituted tricyclic isoxazoline derivatives and their use as anti-depressants
EP1554286B1 (en) * 2002-08-15 2010-01-27 Janssen Pharmaceutica N.V. Fused heterocyclic isoxazoline derivatives and their use as anti-depressants
AU2003271567B2 (en) * 2002-08-21 2009-12-24 Janssen Pharmaceutica N.V. C6- and C9-substituted chromeno (4, 3-C) isoxazoline derivatives and their use as anti-depressants
US8025859B2 (en) 2007-05-18 2011-09-27 Cesl Limited Process for gold and silver recovery from a sulphide concentrate
EP2493866A1 (en) 2009-10-29 2012-09-05 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
WO2018045149A1 (en) 2016-09-02 2018-03-08 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
US11046646B2 (en) 2017-08-09 2021-06-29 Bristol-Myers Squibb Company Alkylphenyl compounds
WO2019032631A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Oxime ether compounds
KR102002633B1 (en) 2018-07-19 2019-07-22 김태효 Non slip foot wear with separating cushion part
KR102429797B1 (en) 2019-12-31 2022-08-05 주식회사 제이패션 Functional non-sewn overshoes and manufacturing method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2119977A1 (en) * 1971-04-23 1971-12-16 Teikoku Hormone Manufacturing Co , Ltd, Tokio Antiphlogistic and antisecretory napththisoxazoles - from 1-hydroxyim - 2-carbonyl derivs by intramolecular condensation
ES2076253T3 (en) * 1989-05-19 1995-11-01 Hoechst Roussel Pharma N- (ARYLOXYALKYL) -HETEROARILPIPERIDINES AND -HETEROARILPIPERAZINAS, A PROCEDURE FOR ITS PREPARATION AND USE AS MEDICINES.
US5670522A (en) * 1992-10-23 1997-09-23 Merck Sharp & Dohme Limited Dopamine receptor subtype ligands

Also Published As

Publication number Publication date
HUP9903706A2 (en) 2000-08-28
CA2241845C (en) 2002-10-01
NO983100L (en) 1998-09-04
IL125197A0 (en) 1999-03-12
AR005347A1 (en) 1999-04-28
CN1214046A (en) 1999-04-14
ZA9725B (en) 1997-07-07
JPH11510816A (en) 1999-09-21
NZ325587A (en) 1999-02-25
KR100308748B1 (en) 2001-12-12
KR19990077033A (en) 1999-10-25
JP3161737B2 (en) 2001-04-25
HUP9903706A3 (en) 2000-09-28
WO1997025317A1 (en) 1997-07-17
AU1412697A (en) 1997-08-01
NO983100D0 (en) 1998-07-03
BR9612578A (en) 1999-07-27
EP0874833A1 (en) 1998-11-04
AU710059B2 (en) 1999-09-09

Similar Documents

Publication Publication Date Title
CA2102179A1 (en) Quinuclidine derivatives
CA2174105A1 (en) Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
AU6944091A (en) Indole-substituted five-membered heteroaromatic compounds
HU906402D0 (en) Process for producing tricyclic carbapeneme derivatives an pharmaceutical preparatives containing these compounds as active substance
TW341565B (en) Indole derivatives processes and intermediates for their preparation and pharmaceutical compositions containing them
HUT61543A (en) Process for producing serotonin antagonist indole derivatives and pharmaceutical compositions comprising same as active ingredient
CA2241845A1 (en) 4,5-dihydronaphth[1,2-c]isoxazoles and derivatives thereof having cns activity
DK1302207T3 (en) Process for preparing an antihypertensive agent containing a dipeptide as an effective ingredient
NO941365L (en) Azabicycloaryl acetylene and aryleneyn oxymers as cholinergic agents and method of treatment
NO892939L (en) PROCEDURE FOR PREPARING BU-3608 DERIVATIVES.
NO974155D0 (en) A novel process for the preparation of 2,3-dihydrobenzofuranol derivatives
AU1925392A (en) A process for the preparation of n-(2,6-dichlorophenyl)-n-phenyl-n-(chloroacetyl)-amine
WO1998029407A3 (en) N-(pyridinylamino)isoindolines for treating alzheimer's and depression
CA2275299A1 (en) Indane or dihydroindole derivatives
EP0657443A4 (en) Optically active carboxamide derivative.
EP0711554A4 (en) Antidepressant
AU2178199A (en) Azetidinecarboxamide derivatives for the treatment of cns disorders
EP1116720A4 (en) Processes for the preparation of isochromanones and intermediates for the preparation thereof
ATE122352T1 (en) 3-(3-ETHYL-1,2,4-OXADIAZOLE-5-YL)-1- AZABICYCLOHEPTAN, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME.
EP0534536A3 (en) Process for the preparation of 2-amino-5,6-dimethoxy-tetralin
AU657423B2 (en) Novel piperidine derivatives and process for preparation thereof
DE69711506D1 (en) Methylsulfomycin 1, process for its preparation and use
DE69611148D1 (en) Pyrrolo (4,3,2-de) quinoline derivative
CA2023951A1 (en) N-hydroxy-dibenz¢b,e!oxepin -alkylamines and -alkanoic acid amides, related heterocyclic analogues, a process for their preparation and their use as medicaments
AU2319000A (en) Thiazolopyrimidine compounds, process for the preparation of the same and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20071212